USITC General Exclusion Order on tirzepatide
This is one entry from the TitrateLab Vendor Graveyard, a dated archive of peptide-market shutdowns, buyer-loss reports and enforcement actions. Documented as April 9, 2025. Evidence tier: Official or peer-reviewed record. Sources for this entry are linked inline below and annotated in the full Vendor Graveyard entry.
The US International Trade Commission, not FDA, issued a general exclusion order on April 9, 2025 barring imports of tirzepatide products that infringe Eli Lilly’s U.S. Trademark No. 6,809,369 or include a false designation of origin.
The order ended investigation 337-TA-1377, which the Commission opened on November 27, 2023 on Lilly’s complaint. Alongside the general order, the Commission issued a limited exclusion order against falsely advertised products from certain defaulting respondents and cease-and-desist orders against others, with a bond of 100% of entered value during the presidential review period. The notice was published in the Federal Register on April 15, 2025 (90 FR 15720).
Evidence tier: Official or peer-reviewed record.